RESEARCH TRIANGLE PARK, N.C., Dec. 13, 2022 -- Pappas Capital, a global venture capital and commercial development firm, announced today the appointment of Richard Staub as Venture Partner. His appointment...
TargeGen announces initiation of clinical trial of JAK2 inhibitor TG101348 in myeloproliferative disease patients
© 2022 Pappas Capital, LLC. ALL RIGHTS RESERVED.